Rm. Vabulas et al., CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses, J IMMUNOL, 164(5), 2000, pp. 2372-2378
MHC class I-restricted T cell epitopes lack immunogenicity unless aided by
IFA or CFA, In an attempt to circumvent the known inflammatory side effects
of IPA and CFA, we analyzed the ability of immunostimulatory CpG-DNA to ac
t as an adjuvant for MHC class I-restricted peptide epitopes, Using the imm
unodominant CDS T cell epitopes, SIINFEKL from OVA or KAVYN-FATM (gp33) fro
m lymphocytic choriomeningitis virus glycoprotein, we observed that CpG-DNA
conveyed immunogenicity to these epitopes leading to primary induction of
peptide-specific CTL, Furthermore, vaccination with the lymphocytic choriom
eningitis virus gp33 peptide triggered not only CTL but also protective ant
iviral defense. We also showed that MNC class I-restricted peptides are con
stitutively presented by immature dendritic cells (DC) within the draining
lymph nodes but failed to induce CTL responses. The use of CpG-DNA as an ad
juvant, however, initiated peptide presenting immature DC progression to pr
ofessional licensed APC, Activated DC induced cytolytic CD8 T cells in wild
-type mice and also mice deficient of Th cells or CD40 ligand, CpG-DNA thus
incites CTL responses toward MHC class I-restricted T cell epitopes in a T
h cell-independent manner. Overall, these results provide new insights into
CpG-DNA-mediated adjuvanticity and may influence future vaccination strate
gies for infectious and perhaps tumor diseases.